@FotoEsqRrR @EricTopol @zeynep @kiranstacey It's much higher in the high risk population where these treatments are authorized, and the data there are strong. For standard/low risk patients it is harder to measure for the reason you suggest.
@FotoEsqRrR@EricTopol@zeynep@kiranstacey在这些治疗获得授权的高危人群中，这一比例要高得多，而且那里的数据非常可靠。对于标准/低风险患者，由于您建议的原因，更难测量。